Jeffrey L. Light

I'll research this attorney to verify background, practice areas, and notable cases.

Let me search more specifically for his profile and case history.

Let me search for his specific profile and credentials.

Professional Summary — Jeffrey L. Light

Focus areas. The one tracked matter for this attorney is Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd., which places his practice in the biologics/pharmaceutical patent space — specifically BPCIA (biosimilar) litigation over Regeneron's aflibercept product EYLEA®. That case is a consolidated MDL proceeding (1:24-md-03103, N.D. W. Va.) involving formulation patents such as U.S. Patent No. 11,084,865. I could not locate a firm-published practice description or bio page for him, so I cannot confirm the full range of technologies he handles or whether he also works in other sectors (chemical, mechanical, electronics, etc.). Treat the technology characterization as inferred from the single case, not from verified practice materials.

Side preference. The tracked record is one appearance, all on the plaintiff/patent-holder side and zero on the defense side, as Lead Counsel. That is consistent with representing brand pharmaceutical companies enforcing patents against biosimilar applicants, though a single data point is a thin basis for characterizing a career-long preference.

Firm context. He is credited to Finnegan, Henderson, Farabow, Garrett & Dunner in the tracked case — an IP-focused firm with a substantial pharmaceutical and biosimilar litigation practice; Finnegan attorneys (e.g., Louis Fogel) appear in the Aflibercept MDL for Regeneron. I could not verify via web search any prior firms, laterals, or an in-house role, so his broader career history is not established here.

Notable matter and outcomes. The Regeneron/Eylea MDL produced significant results: the district court granted preliminary injunctions barring biosimilar launches by Samsung Bioepis, Formycon, and Celltrion based on the '865 patent, and the Federal Circuit largely affirmed (see Regeneron Pharms., Inc. v. Mylan Pharms. Inc., 127 F.4th 896 (Fed. Cir. 2025)). The Samsung Bioepis actions were later resolved by settlement, allowing launch of Opuviz™ in January 2027. These are case-level outcomes; I could not independently verify which specific filings or arguments Mr. Light personally handled.

PTAB / IPR experience. No personalized IPR/PGR record was verifiable from the sources I could reach. The '865 patent at issue has been the subject of multiple IPR petitions filed by Samsung Bioepis and others, but I cannot attribute any of those filings to this attorney.

Disambiguation note. A "Jeffrey Louis Light" appears in public records as a solo practitioner in Washington, D.C., handling FOIA/civil-rights and government-transparency matters — this appears to be a different individual and should not be conflated with the Finnegan patent attorney in the tracked case.

Bar / education. Not reliably sourced; omitted rather than guessed.

Caveat: The above rests on the single tracked appearance plus case-level reporting on the Aflibercept MDL. Because no firm bio or court filing naming Mr. Light's individual role could be verified, his specific contributions, bar admissions, and education remain unconfirmed.